The present invention relates to a pharmaceutical combination formulation comprising vildagliptin or a pharmaceutically acceptable salt of vildagliptin glimepiride or a pharmaceutically acceptable salt of glimepiride and at least one coating layer.

This invention is related to a novel capsule formulation of olmesartan medoxomil having an improved manufacturing process and storage stability furthermore the invention is directed to its use in the treatment of hypertension.

The present invention relates to an orally-disintegrating pharmaceutical formulation which is characterized by comprising flurbiprofen and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

The present invention relates to new pharmaceutical compositions of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly the present invention relates to new pharmaceutical compositions for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders especially with osteoarthritis and rheumatoid arthritis.

Bilayer Tablet Formulations of Flurbiprofen And Glucosamin The present invention relates to a bilayer tablet formulation of flurbiprofen and glucosamine. Particularly the present invention relates to a bilayer tablet formulation having a controlled release flurbiprofen and immediate release glucosamine; furthermore relates to their process and use.

The present invention relates to pharmaceutical formulations of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly the present invention relates to a stable formulation of this combination having desired levels of dissolution rate and solubility which comprises at least one polymer having a low glass transition temperature.